BPC 10mg+GHK-Cu50mg+Tb500 10mg BBG70 High-purity peptides
Reagent Grade
99%
Shenzhen, Shanghai
T&L
10 Vials per Kit
2026-11-08
Peptide,Pharmaceutical raw powder
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
BBG70
Categories:
Research-
Class:
Actin-sequestering protein / 43-amino-acid peptide
Status:Research compound — Not FDA approved (investigational: RGN-259 for dry eye / neurotrophic keratitis)
Mechanism:A naturally occurring 43-amino-acid peptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) that binds G-actin (sequesters monomeric actin), preventing F-actin polymerization. Promotes cell migration, angiogenesis, wound healing, and anti-inflammatory responses via integrin-linked kinase (ILK) and HIF-1α/VEGF pathways. TB-500 is the synthetic fragment Ac-LKKTETQ (MW ~895) often sold under this CAS.
Activity note:Thymosin Beta-4 is an actin-binding protein, not a receptor agonist. Functional activity is measured by actin sequestration (Kd ~0.7–1 μM) and cell migration assays, not EC₅₀.
Source:Goldstein AL, et al. Vitam Horm. 2003;66:257–296. RegeneRx RGN-259 clinical program.DOI
Clinical Development:
References-
DrugBank:PubChem:UNII:Disclaimer:
Thymosin Beta-4 (TB-500) is NOT FDA-approved for human therapeutic use. RGN-259 (Tβ4 ophthalmic solution) is an investigational drug not yet approved. TB-500 sold on research-chemical marketplaces is a synthetic fragment and is not an approved medicine. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Peptide,Pharmaceutical raw powder
-
Location:
No. 188 Kaiyuan Avenue, Science City, Guangzhou High-tech Industrial Development Zone, Huangpu District, Guangzhou
-
Payment Terms:
100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2020
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product